| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424663000 | Chloride | 26 |
| 20090053327 | CONCENTRATED AQUEOUS BROMINE SOLUTIONS AND THEIR PREPARATION - This invention provides concentrated aqueous biocidal solutions formed from bromine chloride, sodium hydroxide, and sulfamic acid. The weight ratio of bromine chloride:sodium hydroxide:sulfamic acid used in forming the concentrated solution is such that for every 10.5 to 11.5 parts by weight of bromine chloride used, 15.3 to 17.5 parts by weight of sodium hydroxide and 11.0 to 12.5 parts by weight of sulfamic acid are used, the biocidal solution containing at least about 100,000 ppm (wt/wt) of active bromine based on the total weight of the solution. | 02-26-2009 |
| 20090110754 | Stabilized Chlorine Dioxide and Hypochlorous Acid in a Liquid Biocide - A liquid biocide containing stabilized chlorine dioxide and hypochlorous acid for various uses, including use as a teat dip or dairy animals. The stable, prophylactic biocide consists essentially of 0.10-20.0% by weight of a chlorite salt, 0.1-3.0% by weight of an acid, 0.10-2.0% by weight of an alkaline agent, and the balance water. Chlorite salt reacts with the acid to form germicidal chlorine dioxide and hypochlorous acid. The acid constituency and the alkaline agent constituency regulate the pH of the solution such that the biocide is stable when mixed for a period greater than two months. The present disclosure also includes a method of producing a stable, prophylactic biocide for dairy cattle, the method comprising 0.10-20.0% by weight of a chlorite salt, 0.10-3.0% by weight of an acid, 0.10-2.0% by weight of an alkaline agent, and the balance water in a container, and sealing the container. In the method, the acid and alkaline agent constituencies regulate the pH of the solution such that the formation of hydronium ions from the acid is correspondingly regulated to stabilize the solution for a period greater than two months from the date of sealing. | 04-30-2009 |
| 20090202659 | Modulation of Peripheral Clocks in Adipose Tissue - Genes encoding the transcription factors controlling the core circadian oscillator (BMAL, Clock, NPAS, Per) and their regulatory targets (Rev-erbα, Rev-erb) have been found in adipose tissue. The circadian pattern of these genes was entrained using restricted feeding. The circadian gene expression profiles were examined in mice and in undifferentiated and adipocyte-differentiated human adipose stem cells following exposure to nuclear hormone receptor ligands (dexamethasone or thiazolidinedione) or 30% fetal bovine serum. All three agents induced the initiation of a cyclic expression profile in representative circadian genes in the human adipose stem cells. The circadian genes studied displayed an oscillatory expression profile, characterized by both a zenith and nadir within a 24-28 hr phase. The circadian gene pattern has been lengthened with use of an inhibitor of glycogen synthase kinase 3 beta. Modulation of the circadian pattern to lengthen or shorten can be used to affect weight gain or loss, respectively. | 08-13-2009 |
| 20090280193 | Enerceutical mediated activation of the Alternative Cellular Energy (ACE) pathway in the therapy of diseases - Alternative cellular energy pigments (ACE-pigments) provide a source of cellular energy other than that provided through the oxidative metabolism of foods, or in the case of plants and certain bacteria, through the process of photosynthesis. In some patients, ACE pigments exist in a form that can be further energized or activated using ultraviolet (UV) light, especially if the reaction is initially triggered by the presence of suitable dyes, such as neutral red. A method is described to further enhance the activation of the ACE pathway in humans and animals deprived of ACE. The method comprises using natural or man-made sources of ACE products (enerceuticals), with or without the inclusion of a suitable dye, such as neutral red; or other activating components, such as magnesium chloride; with the combined mixture being put into a UV transparent container, such as a plastic bag, or placed on some other material, which can be laid onto the skin and illuminated with a UV light source. The process of activating the ACE pathway is evidenced by UV inducible fluorescence seen within areas of the patients' skin and/or mucus membranes. This fluorescence fades as the ACE pathway becomes fully activated. Activating the ACE pathway can have therapeutic benefits in various infectious and non-infectious diseases including illnesses attributed to infections with stealth adapted and conventional viruses and diseases attributed to an inadequacy of the mitochondria and associated metabolic pathways, including states of hypoxia and nutritional deficiencies. | 11-12-2009 |
| 20100291238 | Appetite suppressant product and method - An appetite suppressant composition that is effective for the control of mammalian weight and methods of administration of the composition of the invention are provided. The composition is a cellulose product prepared with ethanol preferably with added sweetener, spice(s), salt and protein for oral administration to a patient. | 11-18-2010 |
| 20110076345 | Herbal Formulation for the Treatment of Bone Fractures and Osseous Defects - An herbal formulation including | 03-31-2011 |
| 20120156313 | CORROSION INHIBITION OF HYPOCHLORITE SOLUTIONS USING SUGAR ACIDS AND Ca - Corrosion inhibitor compositions and methods of use are disclosed. Sugar acids and calcium corrosion inhibitors combined with hypochlorite sources provide use solutions for effective corrosion inhibition for metal surfaces. | 06-21-2012 |
| 20120251631 | METHODS OF TREATING OR PREVENTING PERITONITIS WITH OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION - Provided is a method for treating or preventing peritonitis by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers and can be administered in conjunction with one or more additional therapeutic agents. Further provided is a method for preventing peritoneal hemorrhage, adhesions and abscesses. | 10-04-2012 |
| 20130156867 | Artificial Tear Emulsion - The present invention relates to an oil-in-water emulsion comprising at least one mucomimetic polymer, at least one lipid of phospholipid type, at least one lipid other than the phospholipid, at least one stabilizing polymer, and a hydrophilic liquid, to an emulsion comprising an aqueous phase that contains at least one stabilizing polymer and at least one mucomimetic polymer, and an oily phase that contains at least one lipid of phospholipid type and a lipid other than the phospholipid, to a medicament comprising one of these emulsions, and to the use of one of these emulsions as an agent for restoring and/or replacing the lachrimal film or as a carrier for an active compound. | 06-20-2013 |
| 20130236570 | Use of hypertonic saline to draw fluid out of swollen tissue and relieve nasal congestion - The optimum concentration of salt in solutions to combat congestion of the mucosa is a relatively narrow range. This use of in hypertonic saline solutions for treatment of congestion of the mucosa having a concentration within the range of 2.3% to 2.7% w/v sodium chloride/water with the most preferred concentration being 2.4% to 2.6% w/v of sodium chloride in water brings maximum relief of congestion without causing irritation or discomfort. | 09-12-2013 |
| 20130266667 | Pharmaceutical combination for the treatment of renal failure in pets - The present invention relates to a pharmaceutical combination for the treatment of renal failure in pets, caused by various diseases or ineffective to traditional renal therapy or renal replacement therapy thereby incapable of restoring health. The pharmaceutical combination of the present invention is administered by subcutaneous injection to pets in need thereof, with various advantages including simple use, no requirement for surgery, hospitalization and/or fluid infusion, faster recovery of health status, reduced medical costs, significantly improved recovery rate, reduced mortality and the likes. The pharmaceutical combination of the present invention can also be used for the continuous care treatment of pets with renal failure. | 10-10-2013 |
| 20130280346 | Infusates with Enhanced pH Stability Under Ethylene Oxide Sterilization - Normal saline and other infusate solutions for infusion into the body of a patient during medical treatment are disclosed. In particular, infusates are disclosed that are formulated to resist changes to the pH of the solution when subjected to sterilization procedures that employ ethylene oxide gas. In one embodiment, a buffered infusate suitable for disposal in a syringe or other container is disclosed. The syringe is sterilizable using ethylene oxide. The buffered infusate comprises an aqueous solution that is disposed in the syringe and is suitable for infusion into a body of a patient. A buffer component is added to the aqueous solution to form a buffered solution. The buffer component is configured to resist a change in the pH of the buffered solution upon exposure of the buffered solution to the ethylene oxide during sterilization of the syringe. | 10-24-2013 |
| 20140093586 | ORAL REHYDRATION COMPOSITION - Disclosed are oral rehydration compositions with sucrose, or alternatively fructose and glucose in a 1:1 ratio. The compostion further comprises an osmolarity of below 250 mOsm/L, and sodium below 75 meq/L. Further disclosed are methods of treatment using the same. | 04-03-2014 |
| 20140141101 | COMPOSITIONS OF ENHANCING WOUND HEALING CONTAINING MAGNESIUM AND BROMIDE - The present invention relates to ionic compositions for enhancing wound healing, particularly in the sinonasal cavity. The ionic components of the composition can include potassium, calcium, rubidium, zinc, bromide, and magnesium in an isotonic solution. In other embodiments, the ionic components of the composition can include magnesium, bromide, sulfate, sodium, and chloride. Methods of enhancing wound healing, enhancing sinonasal mucosal healing, promoting mucosal reciliation, and debriding tissue by administering the compositions of the present invention are also presented. | 05-22-2014 |
| 20140370123 | SKIN EXTERNAL COMPOSITION COMPRISING A SEA SALT AND SUGAR AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING VAGINOSIS AND THE USE THEREOF - A skin external composition comprising a combination of salt and sugar as an active ingredient in an amount effective to treat and prevent vaginosis, together with a pharmaceutically acceptable carrier, and the use thereof. | 12-18-2014 |
| 20150030701 | ANTIMICROBIAL COMPOSITIONS AND METHODS - Disclosed are compositions and methods for antimicrobial use. The compositions contain a small antimicrobial agent and a permeabilizing agent. The antimicrobial compositions can be antifungal or antibacterial compositions. | 01-29-2015 |
| 20150044300 | METHOD FOR PREPARING BIOCIDAL AQUEOUS COMPOSITIONS - An aqueous biocidal composition comprising a mixture of hydrochloric acid (HCl), urea, and sodium hypochlorite (NaOCl) at acidic pH, a method for manufacturing the composition and a biocidal technology for treating industrial water. | 02-12-2015 |
| 20150056303 | Electrolytic Magnetic Cell Device and a Method for Producing Hypochlorous Acid and other Disinfectant Chlorine Oxidants - The present invention is directed to a method, system and equipment for the elaboration of electrolytic chlorine oxidants, hypochlorous acid and sodium hypochlorite substances, using elements that result in an ecological process and confers a high efficiency in the production of these substances, permitting the generation of a product of very high performance and efficiency. | 02-26-2015 |
| 20150056304 | GEL, IN PARTICULAR FOR USE IN A WOUND TREATMENT AGENT - A gel, in particular for use in a wound treatment agent includes an inorganic silicate as thickener; and an electrochemically activated aqueous common salt solution having a content of free chlorine of more than 200 mg/l and a conductivity of not more than 12 mS/cm. | 02-26-2015 |
| 20150079200 | SYSTEMS AND METHODS FOR GENERATING GERMICIDAL COMPOSITIONS - The present invention relates to systems and methods for generating germicidal compositions for use in a wide variety of settings, including agricultural settings (e.g., animal bedding), food production settings, hospitality settings, health care settings, health club settings, exercise facility settings, research based settings, veterinarian settings, medical settings, hydraulic fracturing settings, and/or any setting requiring disinfection. | 03-19-2015 |
| 20150104527 | AQUEOUS IONIC SOLUTION CONTAINING SEAWATER AND AT LEAST ONE COMPOUND THAT IS ORIGINALLY IMMISCIBLE WITH SEA WATER - The invention relates to an aqueous ionic solution, particularly for nasal use, including: at least one seawater solution having an osmolality of between 290 mOsm/kg and 400 mOsm/kg in a weight proportion of between about 30 and 98 wt % relative to the total weight of the composition; at least one cationic phospholipid of natural origin in a weight proportion of between about 0.01 and 5 wt % relative to the total weight of the composition; and at least one compound, which is originally immiscible with said seawater solution, in a weight proportion of between 0.01 and 10 wt % relative to the total weight of the composition. | 04-16-2015 |
| 20150140127 | METHOD FOR DETECTING INJURY TO THE BRAIN - Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination thereof; b) comparing the level of the TJ protein in the test sample to the level of the TJ protein in a control sample, wherein an elevated level of the TJ protein in the test sample relative to the level of the TJ protein in the control sample indicates that the subject has an injury to the brain. | 05-21-2015 |
| 20160044927 | Disinfectant Formulation Comprising Calcium Hydroxide and Sodium Hypochlorite - The application relates to disinfectant formulations comprising calcium hydroxide and sodium hypochlorite and further relates to a method of manufacturing the disinfectant formulations and methods of disinfecting an object using the disinfectant formulations. | 02-18-2016 |
| 20160192659 | METHOD FOR PREPARING BIOCIDAL AND ANTIFOULING AQUEOUS COMPOSITIONS COMPRISING HYDROBROMIC ACID, UREA AND SODIUM HYPOCHLORITE | 07-07-2016 |
| 424664000 | Ammonium chloride | 2 |
| 20110045103 | METHODS FOR TREATING AIDS - The present invention pertains to methods of inactivating human immunodeficiency virus (HIV), both in vitro and in vivo. Such methods also relate to treating HIV-related symptoms and the treatment of acquired immune deficiency syndrome in patients. Methods typically employ administering a composition comprising ammonium chloride such that HIV is inactivated. | 02-24-2011 |
| 20150313937 | Solution And Method For Treating Cancer - Cancer has been a persistent, serious health problem for several decades. The present invention relates to a chemical solution of relatively common chemicals that can be mixed and injected into a patient to destroy existing cancer cells or to immunize people from cancer. The solution is mixed using four distinct vials holding different chemicals according to a certain protocol. The resulting solution is injected into a patient according to a specific dosing regimen. | 11-05-2015 |
